Tout­ing a wad of cash in the wake of a clin­i­cal im­plo­sion, a small biotech re­views some lim­it­ed op­tions

Just two short months af­ter TYME Tech­nolo­gies’ lead drug can­di­date SM-88 was pulled from a failed Phase II/III tri­al for metasta­t­ic pan­cre­at­ic can­cer, the mi­cro­cap …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER